NEFH

Across TCGA pan-cancer cohorts, NEFH mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of NEFH’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where NEFH mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types NEFH is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, CCRCC, and LUAD are the cancer types where NEFH tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NEFH mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	−1.895	<.001	11	view →
CCRCC	Male	All	+0.504	.001	3	view →
LUAD	All	II,III,IV	−0.302	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

NEFH–HNSC

Open the HNSC breakdown →